A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs AZD 5363 (Primary)
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Male breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Jun 2017 Planned primary completion date changed from 27 May 2018 to 31 May 2018.
- 10 Apr 2017 Planned End Date changed from 1 Apr 2018 to 28 Dec 2018.
- 10 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 27 May 2018.